Patented cancer vaccines: The promising leads

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 5, 2010, Pages 647-660

  Aurisicchio, Luigi ^a,b   Ciliberto, Gennaro ^a,b  

^a Grande Ospedale Metropolitano   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Immunomodulators; Immunotherapy; Recombinant vectors; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; DNA VACCINE; NANOPARTICLE; PEPTIDE VACCINE; TUMOR ANTIGEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; CELL THERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; CONSENSUS; ENGINEERING; GENETIC IMMUNIZATION; HUMAN; NONHUMAN; PATENT; REVIEW; SURVIVAL TIME; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC; VACCINES, SUBUNIT;

EID: 77951554477     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003720483     Document Type: Review

References (112)

1. Available from: http://www. researchandmarkets.com/research/2a2448/ launching-next-gen
2. Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics 2009;12(5-6):319-330
3. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci 2009;46(4):167-189
4. Available from: http://www. MarketResearch.com
5. Available from: http://www.fda.gov/ BiologicsBloodVaccines/ GuidanceComplianceRegulatory Information/Guidances/Vaccines/ ucm182443.htm
6. Available from: http://www. kaloramainformation.com/
7. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353(9150):345-350 (Pubitemid 29088160)
8. Berd D, Sato T, Maguire HC, et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22(3):403-415 (Pubitemid 41079768)
9. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-599 (Pubitemid 38264176)
10. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, et al. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008;57(10):1569-1577
11. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006;25(5-6):321-352 (Pubitemid 44972270)
12. H Lee Moffitt Cancer Center and Research Institute Inc. Chemokine gene-modified cells for cancer immunotherapy. WO2009117566; 2009
13. Kallen KJ, zum Buschenfelde KH, Rose-John S. The therapeutic potential of interleukin-6 hyperagonists and antagonists. Expert Opin Investig Drugs 1997;6(3):237-266 (Pubitemid 27141791)
14. AGIRx Limited, UK. Anticancer vaccine compositions comprising allogenic tumor cells modified with hyper-cytokines, particularly for the treatment of melanoma. WO2009095261; 2009
15. Morphogenesis, Inc. Tumor cell vaccines. WO2009117011; 2009
16. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24(21):4582-4585
17. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9(4):1284-1290 (Pubitemid 36418378)
18. Liao JC, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006;6:8 (Pubitemid 44030595)
19. Peruzzi D, Mesiti G, Ciliberto G, et al. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010;28(5):1201-1208
20. Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009;9(10):611-616
21. Ribas A, Butterfield LH, Glaspy JA, et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21(12):2415-2432 (Pubitemid 46621880)
22. University of Miami. Immunotherapy based on allogeneic cancer cells secreting a modified heat shock protein, such as gp96. WO2009114085; 2009
23. Campi G, Crosti M, Consogno G, et al. CD4+ T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 2003;63:8481-8486 (Pubitemid 37549504)
24. Frenoy N, Schauffler J, Cahour A, Burtin P. Natural antibodies against the carcinoembryonic antigen (CEA) and a related antigen, NCA, in human sera. Anticancer Res 1987;7:1229-1233 . One of the first papers characterising tumour associated antigens belonging to CEA superfamily. (Pubitemid 18062725)
25. Fuchs C, Krapf F, Kern P, et al. CEA-containing immune complexes in sera of patients with colorectal and breast cancer: analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 1988;26:180-184 (Pubitemid 18098871)
26. Huarte E, Sarobe P, Lasarte JJ, et al. Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembrynic antigen. Int J Cancer 2002;97:58-63 (Pubitemid 33104395)
27. Kawashima I, Hudson SJ, Tsai V, et al. The multiepitope approach for immunotherapy for cancer: identification of several CTL epitopes from tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1-14 (Pubitemid 28141258)
28. Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol 2003;30(3 Suppl 8):30-36 (Pubitemid 36897517)
29. Shumway NM, Ibrahim N, Ponniah S, et al. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009;23(5):277-287
30. Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 2008;90(1):173-180
31. Chaudry MA, Sales K, Ruf P, et al. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 2007;96(7):1013-1019 (Pubitemid 46608303)
32. Andersen MH, thor SP. Survivin--a universal tumor antigen. Histol Histopathol 2002;17(2):669-675
33. Doehn C, Bohmer T, Kausch I, et al. Prostate cancer vaccines: current status and future potential. BioDrugs 2008;22(2):71-84 (Pubitemid 351414750)
34. Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006;5(5):707-716 (Pubitemid 46021051)
35. Cavallo F, Offringa R, van der Burg SH, et al. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006;90:175-213 (Pubitemid 43765801)
36. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117(5):1195-1203 (Pubitemid 46718404)
37. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009;27(25):4047-4054
38. Yuan J, Ku GY, Gallardo HF, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009;9:5
39. Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010;116(2):292-301
40. Miyazawa M, Ohsawa R, Tsunoda T, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010;101(2):433-39(7)
41. Rhovac ApS, Den. Rhoc-based immunotherapy. WO2009076966; 2009
42. Clark EA, Golub TR, Lander ES, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406(6795):532-535
43. Kleer CG, van Golen KL, Zhang Y, et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002;160(2):579-584 (Pubitemid 34160335)
44. Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83(6):861-870 (Pubitemid 36723695)
45. Caprion Pharmaceutical Inc. Lung cancer-associated tumor antigen TAT-039, and methods of assessing and treating cancer. WO2007089659; 2007
46. Agensys, Inc. Nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer. US7585505; 2009
47. Kebache S, Ash J, Annis MG, et al. Grb10 and active Raf-1 kinase promote Bad-dependent cell survival. J Biol Chem 2007;282(30):21873-21883 (Pubitemid 47195782)
48. University of Illinois. Mammalian cell expressing tumor-associated antigen Grb10 or others as vaccine for cancer therapy. WO2009114816; 2009
49. Sood A. Anti-PDEF (prostate-derived Ets factor) antibodies for diagnosing and treating cancer, as well as PDEF-comprising tumor vaccines. US20090202595; 2009
50. Wei L, Shi YB. Matrix metalloproteinase stromelysin-3 in development and pathogenesis. Histol Histopathol 2005;20(1):177-185 (Pubitemid 40028996)
51. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-174 (Pubitemid 37328786)
52. Mari BP, Anderson IC, Mari SE, et al. Stromelysin-3 is induced in tumor/ stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem 1998;273(1):618-626
53. Peruzzi D, Mori F, Conforti A, et al. MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res 2009;15(12):4104-4113
54. Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Matrix Metalloproteinase 11 Vaccine. WO2007042169; 2007
55. Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 2004;1695(1-3):225-233 (Pubitemid 39574976)
56. Kapil M. DNA Vaccine for Cancer Therapy. US2009221682; 2009
57. Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof WO2008043760; 2008
58. Mennuni C, Ugel S, Mori F, et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008;68(23):9865-9874
59. Dharmapuri S, Peruzzi D, Mennuni C, et al. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther 2009;17:1804-1813 . The pleiotropic effects of TLR9 immune modulation are shown in combination with a cancer vaccine.
60. Jacobs JF, Aarntzen EH, Sibelt LA, et al. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 2009;58(1):145-151
61. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247(4944):824-830 (Pubitemid 20078558)
62. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-1037 (Pubitemid 32267972)
63. Goddard AD, Borrow J, Freemont PS, et al. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991;254(5036):1371-1374 (Pubitemid 21917471)
64. Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol 2009;16(3):145-153
65. Arizona State University. Peptide variants associated with somatic mutation in cancer and their use in the diagnosis and immunotherapy of cancer WO2007101227; 2007
66. Genitope Corporation. Vaccines comprising surface antigen epitope and surface antigen-specific monoclonal antibody for combination immunotherapy of B cell malignancy. WO2007067780; 2007
67. University of California. Glycopeptides comprising tumor-associated carbohydrate antigen that direct against CTLs or helper T cells for immunotherapy of carcinomas. WO2009108807; 2009
68. Franco A. Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions. Anticancer Agents Med Chem 2008;8(1):86-91 (Pubitemid 351445063)
69. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49(24 Pt 1):7045-7050 (Pubitemid 20016591)
70. Memorial Sloan-Kettering Cancer. Glycoconjugates comprising carbohydrate epitopes, methods for their synthesis, and their use for the treatment or prophylaxis of cancer. WO2004011476; 2004
71. University of Georgia Research Foundation, Inc. Glycolipopeptides and uses thereof in vaccines. US20090041836; 2009
72. The Scripps Research Institute, USA. Antigen or self-antigen genetically encoded unnatural amino acid for breaking immune tolerance and treating cancer, infection or autoimmune disease. WO2009099672; 2009
73. Sette A, Alexander J, Ruppert J, et al. Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol 1994;12:413-431 (Pubitemid 24140420)
74. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50(3-4):213-219 (Pubitemid 30099526)
75. Merck & Co., Inc. System and method for automated selection of T-cell epitopes. WO2006124408; 2006
76. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190(3):355-366 (Pubitemid 29374833)
77. Ludewig B, Ochsenbein AF, Odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191(5):795-804
78. Keogh E, Fikes J, Southwood S, et al. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001;167(2):787-796 (Pubitemid 32660833)
79. Epimmune, Inc. HLA binding motifs and immunogenic peptides and their uses for vaccines against desired antigens. US20070055049; 2007
80. Henry M. Jackson Foundation for the Advancement of Military Medicine Institute. Targeted identification of immunogenic peptides. WO2009112792; 2009
81. Aparna Biosciences, USA. Therapeutic and vaccine polyelectrolyte nanoparticle compositions. WO2009079066; 2009
82. Alpha-O Peptides AG, Switz. Self-assembling peptide nanoparticles comprising T cell epitopes and/or B cell epitopes useful as vaccines. WO2009109428; 2009
83. Wuest T, Both GW, Prince AM, et al. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004;22(21-22):2717-2721 (Pubitemid 38900646)
84. McCoy K, Tatsis N, Korioth-Schmitz B, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007;81(12):6594-6604 (Pubitemid 46878063)
85. Tatsis N, Tesema L, Robinson ER, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006;13(5):421-429
86. Zhi Y, Figueredo J, Kobinger GP, et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 2006;17(5):500-506 (Pubitemid 43794489)
87. Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 2005;79(23):14595-14605 (Pubitemid 41636258)
88. Perreau M, Mennechet F, Serratrice N, et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 2007;81(7):3272-3284 (Pubitemid 46456636)
89. Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 2004;105(2):127-136
90. Peruzzi D, Dharmapuri S, Cirillo A, et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009;27(9):1293-1300
91. Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Chimpanzee adenovirus vaccine carriers. WO2005071093; 2005
92. The Trustees of the University of Pennsylvania, USA. Sequences for simian adenoviruses of subfamily C, SAdV-40, SAdV-31 or SAdV-34, and uses thereof for gene delivery, vaccination and recombinant production. WO2009105084; 2009
93. Brockstedt DG, Dubensky TW. Promises and challenges for the development of Listeria monocytogenes-base immunotherapies. Expert Rev Vaccines 2008;7(7):1069-1084
94. Paterson Y, Maciag P, Seavey M, et al. Recombinant Listeria expressing High Molecular Weight Melanoma-Associated Antigen Protein (HMW-MAA) and fragments thereof, and methods of use thereof for cancer immunotherapy. US 20090202587; 2009
95. Cerus Corporation, USA; Anza Therapeutics, Inc. Inactivated Listeria comprising plasmid vector encoding holin protein and tumor antigen or infectious agent antigen as vaccines against cancer and infection. WO2008027560; 2008
96. GlobeImmune Inc. Yeast-based vaccine for inducing an immune response. WO2007092792; 2007
97. GlobeImmune Inc. Ras mutations and compositions and methods related thereto. WO2007133835; 2007
98. Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Peop. Rep. China Recombinant plasmodium for expressing exogenous gene of vaccine and antigen. CN101492643; 2009
99. University of California. Immunostimulatory combinations of receptor agonists for vaccines and tumor immunotherapy. WO2007120368; 2007
100. University of Pennsylvania. Methods and compositions for modulating T cell homing to solid tumors to enhance immunotherapy of tumor vaccines. US20090214518; 2009
101. Masotti A, Ortaggi G. Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Rev Med Chem 2009;9(4):463-469
102. United States Dept. of Health and Human Services, US. Chitosan enhancement of immune responses. WO2008039390; 2008
103. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008;13(Suppl 4):2-9
104. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 2008;13(Suppl 4):10-15
105. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008;13(Suppl 4):16-25
106. Medarex, Inc. Anti-CTLA-4 antibodies with no CTLA-4-B7 binding inhibition for inducing T cell response to antigenic stimulation and treating cancer. WO2009100140; 2009
107. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27(2):161-167
108. Coley Pharmaceuticals GmbH. Immunostimulatory P-class oligonucleotide formulations for use in treating diseases and as vaccine adjuvants. WO2007095316; 2007
109. van der Most RG, Currie A, Robinson BW, et al. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006;66(2):601-604 (Pubitemid 43165917)
110. Bracci L, Moschella F, Sestili P, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007;13(2 Pt 1):644-653 (Pubitemid 46225372)
111. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641-648 (Pubitemid 46348738)
112. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-854